Subscribe to news

Sberbank Finances Construction of HSCI’s New Laboratory and Production Complex

On August 3, 2012, Moscow bank of Sberbank of Russia and the Human Stem Cells Institute (“HSCI”, MICEX: ISKJ) completed signing of the set of agreements on financing in the amount of 75 million rubles for the construction and equipping of a new laboratory and production complex which will serve as an important platform for providing HSCI’s innovative services.

The design and construction of this complex, which has no analogues in Russia, began in 2011. Its creation is a strategically important step not only for HSCI but for the Russian biotech sector as a whole. In addition to Company’s own drugs and services, the complex will also serve as a platform for contract production of the products of other Russian and international companies.

The complex will include cleanroom laboratory and production premises totaling 360 square meters. In addition, there will be 200 square meters of space for a modern automated cryogenic facility for the storage of cell-based drugs and products in deep freeze (-196ºС). According to plans, the complex will be GMP, GLP and ISO certified.

The laboratory and production complex will include:

  • Molecular genetics laboratory – for diagnosis of inherited diseases, including using the unique Gemascreen DNA arrays, and for providing the full spectrum of services for pre-implantation genetic diagnosis (PGD) for IVF clinics in the Russian Federation;  
  • Cell culture products laboratory – for development and production of tissue-engineering products and the provision of services based on cell technologies: personalized SPRS-therapy and SPRG-therapy (applying autologous fibroblasts to correct the effects of aging & skin damage and to  restore periodontal soft tissue, respectively) as well as the creation of tissue-engineered transplants;
  • Pharmaceutical block – for development, production and quality control of cell-based drugs;
  • Cord blood stem cell bank – for cryogenic storage of the umbilical cord blood of newborns;
  • Reproductive tissue bank – for the collection, genetic testing for inherited diseases and personal storage of reproductive cells and tissues.


HSCI has initiated the construction of this laboratory and production complex using its own funds without the participation of state development institutions, and the partial financing of this project using Sberbank’s credit resources is very important for the Company. The Company plans to complete work on the creation of the complex by the end of 2012.

Artur Isaev, General Director of HSCI, commented: “The creation of our own laboratory and production complex is necessary for the scaling of HSCI’s drugs and technologies which have received marketing authorization as well as for the development of new products. Today the institute already has a licensed laboratory for working with cell cultures and for the provision of Gemabank and SPRS-therapy services. It complies with the highest laboratory standards. However, its cleanroom space of 60 square meters is already not sufficient for the promising and growing market for HSCI’s new products. The new laboratory is certain to meet HSCI’s needs for the next 3-4 years even in the case of intensive growth in demand for HSCI’s services and drugs.”

Full Version of the Press Release (233 kb)

09 August 2012